Literature DB >> 10231715

Syntheses and biological activities of potent bombesin receptor antagonists.

M Llinares1, C Devin, O Chaloin, J Azay, A M Noel-Artis, N Bernad, J A Fehrentz, J Martinez.   

Abstract

Bombesin receptor antagonists are potential therapeutic agents due to their ability to act as inhibitors of cellular proliferation. On the basis of our hypothesis concerning the mechanism of action of gastrin associating an activating enzyme to the receptor and on the results reported in the literature, we have synthesized bombesin analogs which have been modified in the C-terminal part. Potent bombesin receptor antagonists were obtained by replacement of Leu-13 with a statyl residue or with a residue bearing an hydroxyl group in place of the carbonyl function of Leu-13. Several inhibitors were able to recognize the bombesin receptor on rat pancreatic acini and antagonized bombesin stimulated amylase secretion in the nanomolar range. These compounds were also able to recognize the bombesin receptor and to inhibit [3H] thymidine incorporation in 3T3 cells with the same potency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231715     DOI: 10.1034/j.1399-3011.1999.00028.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  15 in total

1.  A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer.

Authors:  Jelena Levi; Ataya Sathirachinda; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

Review 2.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.

Authors:  Rosalba Mansi; Xuejuan Wang; Flavio Forrer; Beatrice Waser; Renzo Cescato; Keith Graham; Sandra Borkowski; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

5.  A human GRPr-transfected Ace-1 canine prostate cancer model in mice.

Authors:  Haiming Ding; Shankaran Kothandaraman; Li Gong; Michelle M Williams; Wessel P Dirksen; Thomas J Rosol; Michael F Tweedle
Journal:  Prostate       Date:  2016-03-04       Impact factor: 4.104

Review 6.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

Review 7.  Novel insect control agents based on neuropeptide antagonists: The PK/PBAN family as a case study.

Authors:  Miriam Altstein
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 2.866

8.  Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors.

Authors:  Antonella Accardo; Filippo Galli; Rosalba Mansi; Luigi Del Pozzo; Michela Aurilio; Anna Morisco; Paola Ringhieri; Alberto Signore; Giancarlo Morelli; Luigi Aloj
Journal:  EJNMMI Res       Date:  2016-02-20       Impact factor: 3.138

9.  High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.

Authors:  Bogdan Mitran; Helge Thisgaard; Ulrika Rosenström; Johan Hygum Dam; Mats Larhed; Vladimir Tolmachev; Anna Orlova
Journal:  Contrast Media Mol Imaging       Date:  2017-08-10       Impact factor: 3.161

Review 10.  Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.

Authors:  Sandra Bednarova; Maria L Lindenberg; Maria Vinsensia; Chiara Zuiani; Peter L Choyke; Baris Turkbey
Journal:  Transl Androl Urol       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.